Browsing: Johnson & Johnson

Johnson & Johnson has recalled five of its aerosol sunscreen products.

The firm announced on Wednesday that it would like to voluntarily recall all lots of five EUTROGENA^® and AVEENO^® aerosol sunscreen product lines to the consumer level.

“Internal testing identified low levels of benzene in some samples of the products. Consumers should stop using the affected products and follow the instructions set forth below.” The healthcare giant said in a statement.

What Benzene really is

According to an information kit from the Center for Disease Control and Prevention (CDC), benzene is a chemical that is a colourless or light yellow liquid at room temperature. It has a sweet odour and is highly flammable.

CDC says that direct exposure of the eyes, skin, or lungs to benzene could cause tissue injury and irritation however, presenting with these signs and symptoms does not necessarily mean that a person has …

Africa’s second top economy, South Africa is yet unhinged with the grilling impacts of the coronavirus, which has already taken more than 58,000 lives and infected more than 1.7 million in the country.

“In view of the rising infections, we have therefore decided to move the country to Alert Level 3.This will take effect later this evening once the regulations have been gazetted,” South African President Cyril Ramaphosa said on Tuesday.

According to President Ramaphosa speech, different issues related to the adoption of the new alert level were raised and the national leader rallied people to embrace the new precautions for the longevity of the nation.

“We know that as difficult as the last 15 months have been, we have started to recover and rebuild. Although it has encountered several setbacks, our mass vaccination programme is gaining momentum and we are finally on the path to controlling the disease. But …

Kenya’s Pharmacy and Poisons Board (PPB) has approved the use of a prescription drug manufactured by Janssen, one of the pharmaceutical companies of Johnson & Johnson, for the treatment of prostate cancer.

The local pharmaceuticals regulator has approved the use of Janssen’s once-daily medication ZYTIGA® (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer ahead of a chemotherapy regime.

The approval is expected to help boost ongoing efforts to minimise existing barriers to cancer care access in Kenya.

READ ALSO:Kenya: Prostate cancer patients to get cheaper drugs

The prescription only innovator (non generic) oncological management drug is distributed locally by Janssen Kenya as part of the global pharmaceutical firm’s commitment to enhance access of essential drugs.

Speaking, when he confirmed the recent approval, Janssen Kenya Country Manager Marseille Onyango said prior to the approval, ZYTIGA had only been licensed for treatment of advanced prostate cancer cases post chemotherapy.…